Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma and tissue pharmacokinetics of dermally administered amikacin via impregnated dressings in burn patients
2015-003972-64Phase 3Active
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of amikacin in burn injury and Skin and Soft Tissue Infection (SSTI), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Bacteriological response and resistance. Started Apr 2019; status: active.
02
Drugs
amikacin
03
Conditions
burn injurySkin and Soft Tissue Infection (SSTI)
Beyond the preview
Go deeper on 2015-003972-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003972-64.